Philip D. Lister, Ph.D.
Appointment(s) and Titles:
Professor, Medical Microbiology and ImmunologySecondary Appointment, Pharmacy Sciences
Associate Director, Center for Research in Anti-Infectives and Biotechnology
Director, Graduate Program, Medical Microbiology and Immunology
Education:
B.S., Kansas State University, Microbiology, 1986
M.S., Creighton University, Medical Microbiology, 1989
Ph.D., Creighton University, Medical Microbiology, 1992
Research Interests:
Molecular mechanisms of antibacterial resistance and development of novel antibacterial combinations to prevent the emergence of resistance during therapy.
Selected Publications:
Book Chapters
Lister PD, Hanson ND, Erhardt AF. Pharmacodynamics and Antibacterial Resistance. In CH Nightingale, T Murakawa, GL Drusano, PG Ambrose (Editors), Antimicrobial Pharmacodynamics in Theory and Practice. Marcel Dekker, Inc., New York. 2007:463-485.
Thomson KS and Lister PD. Non-classical Beta-lactams. In SL Gorbach, JG
Bartlett, and NR Barcklow (Editors), Infectious Diseases, 3rd Edition. W.B. Lippencott, Williams & Wilkins, 2004:204-208.
Review Articles
Lister PD and DJ Wolter. Resistance challenges threatening the treatment of Pseudomonas aeruginosa infections with levofloxacin: The role of a levofloxacin-imipenem combination for prevention of resistance. Penetration 2008 (Annual Issue):25-35.
Lister PD. A review of carbapenems in the United States: Focus on doripenem. Expert Reviews in Anti-Infective Therapy. 2007;5:793-809.
Lister PD. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Biochem Pharm 2006;71:1057-1065.
Lister PD. Chromosomally-encoded resistance mechanisms of Pseudomonas
aeruginosa: Therapeutic implications. Am J Pharmacogenomics. 2002;2(4):235-43.
Lister PD. b-Lactamase Inhibitor Combinations with Extended-Spectrum Penicillins: Factors Influencing Antibacterial Activity Against Enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy 2000;20 (Number 9, Supplement 2):213S-218S
Lister PD. Emerging Resistance Problems Among Respiratory Tract Pathogens. The American Journal of Managed Care. 2000:6(Supplement 8):S407-S417.
Research Manuscripts
Lister PD. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. Post-Graduate Medicine 2008;120 (Supplement 3):46-52.
Wolter DJ, Schmidtke AJ, Hanson ND, and Lister PD. Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin. Antimicrobial Agents and Chemotherapy 2007:8:2997-3000.
Lister PD, Wolter D, Wickman P, and Reisbig M. Levofloxacin-imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. J Antimicrob Chemother 2006;57:999-1003.
Wolter D, Hanson ND, Lister PD. AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump. Antimicrobial Agents and Chemotherapy 2005;11:4763-6
Lister PD, Wolter D. Levofloxacin-Imipenem Combination Prevents the Emergence of Resistance Among Clinical Isolates of Pseudomonas aeruginosa. Clinical Infectious Disease 2005;40:S105-14
Wolter D, Hanson ND, and Lister PD. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Letters 2004;236:137-143.
Wolter D, Moland E, Goering R, Hanson ND, Lister PD. Multi-Drug Resistance Associated with mexXY Expression in Clinical Isolates of Pseudomonas aeruginosa from a Texas Hospital, Diagnostic Micro Infect Diseases 2004;50:43-50.
Lister PD. Pharmacodynamics of 500mg and 750mg doses of levofloxacin against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Diseases 2002;44:43-49.
Lister PD. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae: Impact of AUC:MIC ratios on eradication from an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy 2002;46:69-74.
Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin, and sparfloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Journal of Antimicrobial Chemotherapy. 2001;47:811-818.
Lister PD. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and coagulase-negative staphylococci in an in vitro pharmacokinetic model. Clinical Infectious Diseases 2001;32(Suppl 1):S33-38.
Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy. Antimicrobial Agents and Chemotherapy 1999;43:1118-1123.
Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the P. aeruginosa AmpC cephalosporinase at physiologically-relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrobial Agents and Chemotherapy. 1999;43:882-889.
Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 1999;43:79-86.
Lister PD, Sanders, WE, Jr., Sanders CC. Cefepime-aztreonam: a unique double ß-lactam combination for Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1998;42:1610-1619.
Lister PD, Pong A, Chartrand SC, Sanders CC. Rationale behind high-dose amoxicillin therapy for otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother 1997; 41:1926-1932.
Lister PD, Prevan AM, Sanders, CC. Importance of ß-Lactamase Inhibitor Pharmacokinetics in the Pharmacodynamics of Inhibitor-Drug Combinations: Studies with Piperacillin-Tazobactam and Piperacillin-Sulbactam. Antimicrob Agents Chemother 1997; 41:721-727.
Alexov M, Lister PD, Sanders CC. Efficacy of Ampicillin-Sulbactam Is Not Dependent Upon Maintenance of a Critical Ratio Between Components: Sulbactam Pharmacokinetics in Pharmacodynamic Interactions. Antimicrob. Agents Chemother 1996;40:2468-2477.
Lister PD, Gentry MJ, Preheim LC. Granulocyte Colony-Stimulating Factor Protects Control Rats but Not Ethanol-Fed Rats from Fatal Pneumococcal Pneumonia. J Infect Dis 1993;168:922-6.
Lister PD, Gentry MJ, Preheim LC. Ethanol Impairs Neutrophil Chemotaxis In Vitro but Not Adherence or Recruitment to Lungs of Rats with Experimental Pneumococcal Pneumonia. J Infect Dis 1993;167:1131-7.
Lister PD, Mellencamp MA, Preheim LC. Cirrhosis Impairs Serum Bacteriostasis for Escherichia coli. J Lab Clin Med 1992;120:633-8
Current Teaching:
MIC541 – Medical Microbiology & Immunology (Course Director)
Introduction to Medical Microbiology and Immunology. Characteristics of bacteria, gram-negative coccobacilli, gram-negative enterics and miscellaneous bacteria. Antibacterial drugs.
MIC 753 - Antimicrobial Agents and Chemotherapy (Course Director)
Pharmacodynamic of antimicrobials, penicillin-binding proteins, bacteriostatic drugs, antifungal agents, cell-wall active agents, Fluoroquinolones, Glycopeptide resistance.
MIC727 – Methods in Medical Microbiology and Immunology
Thesis preparation and viable count methodologies
ORB135 - Oral Microbiology
Haemophilus, Bordetella,Vibrio, Campylobacter, Group A Streptococcal Sequelae, Bacterial Endocarditis
MIC735 - Diagnostic Microbiology
Antimicrobial susceptibility testing procedures
Antimicrobial Agents and Chemotherapy Mini-Course
Member of Faculty for summer courses for representatives from microbiological and pharmaceutical
industry. Coordinate laboratories and lecture on anti-fungal agents.
Introduction to Clinical Laboratory and Antimicrobial Susceptibility Testing
Pediatric infectious disease fellows, residents, interns, and medical students
Mentoring: Director of Graduate ProgramGraduate Student PhD and MS Committees Professional Activities: NIH, NIAID, and CDC Study SectionsChair, NIAID Regional Centers for Excellence Bioterrorism and Emerging Infectious Diseases (Bacterial Therapeutics) (2008)Chair, NIAID Pharmacodynamic Approaches for Resistance (2008)Chair, NIAID, Biodefense and Emerging Infectious Diseases Programs (2004-5)NIH, SBIR/STTR Microbiology and Infectious Diseases (2001-Present)NIH, Bioengineering Special Emphasis Panel (2007)CDC, MRSA Special Emphasis Panel (2006)NIH, Virology Special Emphasis Panel (2003)
Editorial Boards
Editor, Journal of Antimicrobial Chemotherapy (2008-Present)
Editorial Board, Antimicrobial Agents and Chemotherapy (2002-Present)
Editorial Board, Clinical Microbiology Reviews (2002-Present)
Editorial Board, European Journal of Clinical Microbiology (2003-Present)
Editorial Board, Journal of Infectious Disease Pharmacotherapy (2001-2006)
Ad Hoc Reviewer
Diagnostic Microbiology and Infectious Diseases
Journal of Infection
British Journal of Cancer
Clinical Microbiology and Infection
Journal of Applied Microbiology
Clinical Drug Investigation
Drugs
Current Microbiology
Letters in Applied Microbiology
Journal of Pharmacology and Experimental Therapeutics
American Society for Microbiology
Director of Region VI Branches [NE, KS, OK, TX, NM, CO, WY] (2001-2007)
Branch Organizing Committee (2001-2007)
Organizing Committee, Missouri Valley/Texas Branch Joint Meeting (2005)Organizing Committee, Missouri Valley/Missouri Joint Meetings (1997-2003)Foundation for Microbiology Lecturer (2000-2002)
Council Member (1999-2003)
President, Missouri Valley Branch (1997-1999)
President-Elect, Missouri Valley Branch (1995-1997)
Consultant and Advisory Board Positions
Ortho-McNeil Pharmaceutical
Bristol-Myer Squibb
Bayer
Roerig-Pfizer
Rhone-Poulence
Proctor and Gamble
Wyeth-Ayerst Lederle
Honors & Awards:
Nominee, 2007 Creighton University (Teaching for Tomorrow Award)
Pioneer Award - Recognition of leadership role and contribution to the science of hollow fiber bioreactor technology.
Presented at 1997 BioSym International Symposium on Hollow-Fiber Technology
Premier Research Award - Omaha Mid-West Clinical Society 64th Annual Postgraduate Assembly
Who's Who in Science and Engineering
Links:
Center for Research in Anti-Infectives & Biotechnology